The Multicorder: A Handheld Multimodal Metabolomics-on-CMOS Sensing Platform

Abstract

The use of CMOS platforms in medical point-of-care applications, by integrating all steps from sample to data output, has the potential to reduce the diagnostic cost and the time from days to seconds. Here we present the 'Multicorder' technology, a handheld versatile multimodal platform for rapid metabolites quantification. The current platform is composed of a cartridge, a reader and a graphic user interface. The sensing core of the cartridge is the CMOS chip which integrates a 16x16 array of multi-sensor elements. Each element is composed of two optical and one chemical sensor. The platform is therefore capable of performing multi-mode measurements: namely colorimetric, chemiluminescence, pH sensing and surface plasmon resonance. In addition to the reader that is employed for addressing, data digitization and transmission, a tablet computer performs data collection, visualization, analysis and storage. In this paper, we demonstrate colorimetric, chemiluminescence and pH sensing on the same platform by on-chip quantification of different metabolites in their physiological range. The platform we have developed has the potential to lead the way to a new generation of commercial devices in the footsteps of the current commercial glucometers for quick multi-metabolite quantification for both acute and chronic medicines.

A CMOS-Based Multiomics Detection Platform for Simultaneous Quantification of Proteolytically Active Prostate-Specific Antigen and Glutamate in Urine

“…1a. The CMOS chip, including the noise level of the platform, has been fully characterized in previous work [20], [21]. Fig.…”

“…However, this approach limits the use of multi-omics to laboratory testing and does not herald a future POC capability. The use of CMOS-based technology to measure multiple metabolites has previously been demonstrated [10,20,21] but the possibility of measuring proteins and metabolites at the same time has not previously been studied. As a proof-ofconcept aPSA and glutamate were measured in urine as a diagnostic for PCa, the relevance of which has been shown [8,9,14].…”

A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection

“…The chip integrates a 16 × 16 array, or frame, of multisensing elements. Each multisensing element comprises a PD, an ISFET, and a single-photon avalanche diode (SPAD) 53,54 . Only the PDs were used in this work.…”

Eat, Test, Digest: Towards Diagnostic Food for Next-Generation Gastrointestinal Tract Monitoring

“…Currently, ingestible devices are commercially available at an ever-growing rate (CAGR 18.1 %) and an estimated business of $1495 billion by 2027 [14,15]. So far, many ingestible [16][17][18][19][20][21][22][23] and miniaturised [13,[24][25][26][27][28][29] diagnostic platforms have been demonstrated, including systems capable of measuring temperature [21], pH [22], pressure [17][18][19], bleeding [23] or imaging [16,29]. Nevertheless, the material selection remains one of the main limitations of ingestible technology [30].…”